The start-up making drugs in space, then sending them to Australia at 30,870km/h
And then the same capsules are returning to terra firma after travelling at 25 times the speed of sound into our atmosphere?
Why, yes ...
And when they return to Earth, they are returning to Australia?
Yes, again.
'It's actually much less futuristic than it sounds,' says Will Bruey, CEO of Varda Industries, the company launching the drug-factory capsules.
'On average three SpaceX Starlink satellites are launched per day, and our spacecraft is simpler, quite frankly, than a Starlink satellite,' he says.
And, while it's early days for California-based Varda, founded in 2021, the pace of launch for these capsules – whose journey takes them from the US, to low earth orbit, to a South Australian testing range for recovery – is expected to increase.
The start-up is attempting to create a viable business of manufacturing drugs in space, where the lack of gravity unlocks the possibility of new, more effective – and more profitable – drug compounds that can't be made on Earth.
Being in space, the limits on the scale of manufacturing are different to an Earth-bound enterprise – both in the molecular quality of what can be produced and, potentially one day, the scale of the production facility.
For now, the company's future depends on how effectively and profitably it can formulate drugs – or at least the most effective primary active pharmaceutical ingredient – in orbit.
When discussing drug production, Bruey compares microgravity (ultra-low gravity in orbit) to the effect that refrigeration has had on drug production since it was invented.
Before refrigeration existed, people would have asked, how could it create value for pharmaceuticals? Today, refrigeration is a fundamental part of drug and vaccine manufacturing, shipping and storage. It reduces the risk of contamination and helps ensure the drugs are effective. Profitable drug manufacturing would be almost unthinkable without it.
One day, space-based drugs may be discussed the same way. 'The way the pharmaceutical industry will think about [Varda] shortly is just another piece of equipment.'
Even the name of the spacecraft – the W in Varda's W-series capsule – unofficially stands for 'Winnebago' (or caravan in American English) used in TV series Breaking Bad, which is itself a story about the remote, compartmentalised cooking up of drugs.
'Instead of going to the desert, we're going to space,' Bruey said.
Likewise, Varda is hauling its equipment to a destination to make its batch, then coming back. 'So that's what we'll be doing. And we'll just be increasing the amount of Winnebagos that are going out to space and back.'
'There's a lot of low-hanging fruit and optimisation to be done in that paradigm.'
Any drug with a formulation improvement worth more than $US200 a gram is viable for Varda to manufacture today. But Varda forecasts it can drive down the cost from $US200 to $US20 'pretty easily by just making our systems more reusable'.
To push lower than that, the company will construct a permanent station with manufacturing equipment that can be used for multiple drugs, Bruey says.
Much of the science around drugmaking in space has been done. There have been numerous experiments on pharmaceuticals, for example, on the International Space Station.
Varda hopes to have a space-made drug in humans by the end of the decade. In an era of sagging productivity, it's worth considering the value of genre-melding new ventures.
The question is: how much demand is there for a service that is new to the world? And on Earth – in Australia – how many re-entries could we see?
Adelaide-based company, Southern Launch, was formed in 2017 as a spaceport operator providing launch services. It has since begun offering orbital re-entry services for customers like Varda.
Their range, at Koonibba in South Australia, enjoys clearer skies with less air traffic than test ranges in the US, giving more flexibility to Varda and other clients, Southern Launch says.
Southern Launch CEO Lloyd Damp said the missions conducted for Varda so far, 'mark an incredible step forward for Australia as the global landing site for re-entries and the in-space manufactured goods the capsules carry.'
Investing in an unproven business model is riskier than investing in say, inner city residential property. But Bruey sees Varda as carving out a niche that can expand as demand grows.
'Basically, there's only four fundamental forces of physics, and gravity is one of them, and we have a knob on [it], and no other company does.' (If you're wondering, the three other forces are: electromagnetism and the strong and weak nuclear forces).
Bruey knows about physics because he studied the subject at Cornell University before founding a couple of companies and working at Elon Musk's SpaceX.
Bruey then met up with Delian Asparouhov, who was looking to invest in a company that could do this work. Asparouhov was looking for someone with Bruey's background and who 'was willing to drop everything and go on this adventure'.
Varda now has backing from Khosla Ventures, Lux Capital, Caffeinated Capital, Founders Fund, and General Catalyst. It has raised $US187 million in a new funding round this month, bringing the total capital raised to $US329 million.
The bet that money can be made by low-orbit manufacturing has caught the attention of SpaceX, which reportedly has plans to get into the space-drug game by manufacturing too.
Elon Musk's company plans to use its massive – and recently unlucky – Starship rocket for the purpose, according to Bloomberg. Sources close to Varda call the report about SpaceX's plan, called Starfall, a 'validation' of Varda's business model.
Like SpaceX, Varda's goal isn't science, it's business: advanced, space-tech business, with the potential to unlock a huge new market that could one day involve large in-orbit factories. The in-space manufacturing market could be worth $US10 billion in five years, according to McKinsey.
But exploiting a fundamental force of physics for profit comes with some hard realities. If you send the capsule into space, you must find a reliable place to recover the spacecraft – closing the loop on the production process.
That's where Australia comes in.
Varda's first craft W-1, launched in June 2023, was due to return in July, but instead got delayed as the company sought permission for the landing in Utah. It remained in orbit for eight months while the details of a new license were resolved between government authorities.
While W-1 was in orbit, Varda reached out to Australia's space industry, looking for reliable space return services.
W-1's February 2024 return coincided with Varda being granted a 'Part 450 re-entry license' from the FAA's Office of Space Transportation, part of a new process to accommodate repeated missions common in commercial space.
Varda now has a FAA license which allows the company to launch and re-enter a craft without spelling out the identical parameters of the mission on repeated applications.
When Varda's W-2 landed in South Australia, Enrico Palermo, head of the Australian Space Agency said it highlighted 'the opportunity for Australia to become a responsible launch and return hub for the global space community, capitalising off the geographic advantages of our expansive continent.'
Unlike crewed missions, which must gently skim into the atmosphere without burning up to bring humans safely home, Varda's missions comes in 'ballistically, as if it's like a missile'.
In that phase, the Winnebagos achieve Mach 25, twenty-five times the speed of sound, or 30,870 kilometres per hour.
Varda has attached a camera to the capsule to capture the dramatic re-entry footage, which looks something like a gas log on overdrive. In space.
The pink glow you see is plasma, Bruey says, from the capsule moving so fast and creating so much heat 'it's literally ripping the molecules in the atmosphere apart and ripping away their electrons'.
'The streaks of what looks like fire is the heat shield 'ablating', that is the little pieces coming off intentionally to take away the heat, shedding it from the spacecraft.'
So far, Varda has created a crystal form of an HIV drug ritonavir in space.
It has research collaborations with large pharma brands, whose names Varda would not give, citing non-disclosure agreements.
W-2 and W-3 landed in February and May 2025 at Koonibba Test Range in South Australia. W-4 is currently in orbit. Varda says it is on track for four missions in 2025 – with plans to expand to a double-capsule mission in 2026. From there, the pace is expected to increase to a weekly pace.
Veteran space industry observer and contributor Brett Biddington says Australia is 'well-suited to support the recovery of payloads from space' with a historical record that is 'unblemished'.
'Whether a viable business can be made just from recovery support is another question,' he says.
He expects that the 'activity will be lumpy and sporadic' and can best thought of as a 'supplementary income stream' to one that is more reliable.
Varda's plan isn't to create a new business alone, but the industry needed to support and grow the enterprise.
With the capsules going up and coming back, we will soon know if Varda is successful.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
an hour ago
- ABC News
As South Australia deals with its algal bloom, California is dealing with another
A dead sea lion is discovered on one end of the coast, and not far away an entire pod of long-beaked common dolphins lay stranded. It is becoming a familiar scene for those living along the coast of Southern California. And much like in South Australia, where thousands of dead sea creatures have washed ashore since March, a harmful algal bloom is to blame. Warning: This story contains content that some readers may find distressing. In California, this is the fourth consecutive year of death and destruction along the coastline. There have been scores of marine mammals and sea birds injured and killed, with US rescuers dealing with "by far historically the largest mass stranding event" relating to algal blooms. In South Australia, the Karenia mikimotoi bloom, kills fish and other sea creatures by impacting their gills, causing them to drown. In the US, authorities have been dealing with different types of algae, including one that produces domoic acid which can cause mammals like sea lions to experience seizures, behave aggressively or die. The Pacific Marine Mammal Center (PMMC) said the harmful algal bloom on the Southern California coast had significantly impacted sea lion and common dolphin populations and had killed two humpback whales and a minke whale. "In 2025, we've experienced the worst domoic acid algae bloom that we've ever experienced in Southern California history," Alissa Deming, PMMC vice president of Conservation, Medicine and Science told ABC News. Dr Deming said the PMMC hospital had taken in hundreds of sick mammals, which had been "physically demanding and very emotionally taxing" on staff and volunteers trying to help while protecting the public from aggressive animals. "A number of the sea lions were also pregnant, and that resulted in reproductive losses of over 85 fetuses born and lost in our hospital as a result of this bloom," she said. The veterinarian said there were likely similar drivers for its bloom to the one happening in South Australia including increasing marine temperatures and more nutrients from cold water upwelling. "By combining the warm sea surface temperatures with increased nutrients, that has resulted in us having a bloom event every year since 2022, with them seemingly becoming larger, longer lasting and covering a lot larger geographic region," Dr Deming said. Investigations are underway if the destructive Los Angeles wildfires in January and the associated run-off have contributed to the bloom. The US National Office for Harmful Algal Blooms said a conservative estimated cost of harmful algal blooms for the the US was about $50 million, but experts say expenses are hard to quantify. A 2024 study estimated losses to tourism-related businesses during the 2018 Florida red tide bloom at $US2.7 billion. Dr Deming said the US government agencies continued to have monitoring and management practices in place to support the commercial seafood industry. "Being able to have good federal and state agencies that can do surveillance to test to ensure seafood is safe for the public, as well as trying to come up with preventative measures or best management practices to prevent blooms, … are really high priority items," she said. "We're happy we have some of those systems in place, but there's absolutely room for improvement I think all around the world to help prevent the conditions that support these really long lasting and devastating blooms." Other algal blooms have also wreaked havoc in other parts of the world. An algae surge choked to death an estimated 40,000 tonnes of salmon in Chile in 2016 while hundreds of elephant deaths in Botswana in 2020 were linked to cyanobacteria, often called blue-green algae in Australia. The scale of each harmful algal bloom event seems to be increasing, professor Gretta Pecl from the University of Tasmania's Institute for Marine and Antarctic Studies told the ABC. "If there isn't something done to mitigate, to reduce climate emissions, warming will continue and these kinds of events will be more and more likely," she said. US research biologist at NOAA Fisheries Kathi Lefebvre, who has been studying harmful algal blooms for 25 years, said the blooms were getting worse and reaching areas "where we used to not have problems". "It is turning out to be a major impact of climate change." Authorities in South Australia have linked South Australia's algal bloom to climate change, and state and federal governments have pledged a collective $28 million for a suite of measures to tackle the algal bloom, including more funding for testing. Dr Lefebvre said authorities needed to take action now to mitigate the effects of future blooms. "What's going to happen if these blooms are going to be continuing is that there's going to need to be ways to test for toxins … to protect human health," Dr Lefebvre said. "The more information we have, the better decisions we can make.

Sydney Morning Herald
2 hours ago
- Sydney Morning Herald
Ansett Australia is back. But not as you know it
It was once Australia's second-largest airline, ferrying more than 10 million passengers around the country every year before it collapsed into administration in 2002. More than 20 years after its final flight, Ansett is making a comeback. Melbourne-based technology entrepreneur Constantine Frantzeskos has revived the Ansett brand, bringing back the iconic Australian airline as an AI-powered travel agency. The Ansett Travel platform, which is now live, is designed as a hyper-personalised travel concierge that will offer predictive trip recommendations and itineraries based on a customers' preference, budget and calendar events. 'Ansett was such a wonderful, innovative brand. It was a pioneer of great service, they were the first ones to bring business class to Australia, and they were loved by their customers,' Frantzeskos said in an interview. 'I thought wouldn't it be a cool thing to genuinely bring this brand back to life. And that's what I'm doing, I'm building the personal travel agent of the future. 'This will be a travel agent that understands you, your family, your needs, your budget and where you've been. That's the vision.' Ansett had operated for 65 years and was the nation's second-largest airline before it was grounded in late 2001, with some 16,000 jobs lost as a result. Its downfall was seen at the time as a 'perfect storm' of poor culture, financial strain, union issues and fleet mismanagement.

The Age
2 hours ago
- The Age
Ansett Australia is back. But not as you know it
It was once Australia's second-largest airline, ferrying more than 10 million passengers around the country every year before it collapsed into administration in 2002. More than 20 years after its final flight, Ansett is making a comeback. Melbourne-based technology entrepreneur Constantine Frantzeskos has revived the Ansett brand, bringing back the iconic Australian airline as an AI-powered travel agency. The Ansett Travel platform, which is now live, is designed as a hyper-personalised travel concierge that will offer predictive trip recommendations and itineraries based on a customers' preference, budget and calendar events. 'Ansett was such a wonderful, innovative brand. It was a pioneer of great service, they were the first ones to bring business class to Australia, and they were loved by their customers,' Frantzeskos said in an interview. 'I thought wouldn't it be a cool thing to genuinely bring this brand back to life. And that's what I'm doing, I'm building the personal travel agent of the future. 'This will be a travel agent that understands you, your family, your needs, your budget and where you've been. That's the vision.' Ansett had operated for 65 years and was the nation's second-largest airline before it was grounded in late 2001, with some 16,000 jobs lost as a result. Its downfall was seen at the time as a 'perfect storm' of poor culture, financial strain, union issues and fleet mismanagement.